Pharmaceutical

Risk adjusted net present value: What is the current valuation of Novartis’s XXB-750?

XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.

Apr 17, 2024 - 00:00
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma

STAT+: FDA investigating whether CAR-T, a treatment for...

Nov 29, 2023

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Eli Lilly reiterates POINT acquisition plans with tende...

Nov 12, 2023

Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis

Novo Nordisk is concluding research on Wegovy’s impact ...

Nov 3, 2023